Keros Therapeutics, Inc.

KROS · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Assets
Cash & Equivalents$693,472$690,215$720,541$559,931
Short-Term Investments$0$0$0$0
Receivables$5,565$17,739$19,374$4,456
Inventory$0$0$0$0
Other Curr. Assets$2,654$2,523$2,939$1,481
Total Curr. Assets$719,307$732,808$759,509$588,893
Property Plant & Equip (Net)$22,027$22,908$23,140$23,488
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$1,449$0$1,449$1,449
Tax Assets$0$0$0$0
Other NC Assets$0$1,449$463$2,056
Total NC Assets$23,476$24,357$25,052$26,993
Other Assets$0$0$0$0
Total Assets$742,783$757,165$784,561$615,886
Liabilities
Payables$2,298$5,267$6,636$4,602
Short-Term Debt$2,318$0$0$0
Tax Payable$0$6,321$10,043$0
Deferred Revenue$155$925$3,308$0
Other Curr. Liab.$10,369$8,514$5,824$416
Total Curr. Liab.$24,092$34,707$39,379$27,450
LT Debt$0$0$0$0
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$0$0$0$0
Total NC Liab.$15,111$15,724$16,311$16,883
Other Liabilities$0$0$0$0
Cap. Leases$0$17,954$18,413$18,861
Total Liabilities$39,203$50,431$55,690$44,333
Equity
Pref Stock$0$0$0$0
Common Stock$4$4$4$4
Retained Earnings-$458,304-$451,024-$420,328-$568,779
AOCI$0$0$0$0
Other Equity$0$0$0$0
Total Equity$703,580$706,734$728,871$571,553
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$742,783$757,165$784,561$615,886
Net Debt-$691,154-$690,215-$720,541-$559,931